Annual Report 2017

Cancer Center Amsterdam
Annual figures CCA 2017

Figure 1: Research staff #

<table>
<thead>
<tr>
<th></th>
<th>VUmc</th>
<th>AMC</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scientific core staff</td>
<td>283</td>
<td>135</td>
<td>418</td>
</tr>
<tr>
<td>Other scientific staff</td>
<td>114</td>
<td>64</td>
<td>178</td>
</tr>
<tr>
<td>PhD students</td>
<td>271</td>
<td>241</td>
<td>512</td>
</tr>
<tr>
<td>Visiting fellows</td>
<td>20</td>
<td>-</td>
<td>20</td>
</tr>
<tr>
<td>Total research staff</td>
<td>688</td>
<td>440</td>
<td>1128</td>
</tr>
</tbody>
</table>

Figure 1a: Research staff # per program

CBI: Cancer biology and immunology
IB: Imaging and biomarkers
TQL: Treatment and quality of life
Note: a researcher can be registered with more than 1 program
Table 2: Main categories of research output

<table>
<thead>
<tr>
<th>Category</th>
<th>VUmc CBI</th>
<th>VUmc IB</th>
<th>VUmc TQL</th>
<th>Total</th>
<th>AMC CBI</th>
<th>AMC IB</th>
<th>AMC TQL</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Refereed articles</td>
<td>163</td>
<td>85</td>
<td>304</td>
<td>552</td>
<td>72</td>
<td>92</td>
<td>339</td>
<td>503</td>
</tr>
<tr>
<td>Non-refereed articles</td>
<td>8</td>
<td>11</td>
<td>21</td>
<td>40</td>
<td>3</td>
<td>1</td>
<td>24</td>
<td>28</td>
</tr>
<tr>
<td>Scientific publications</td>
<td>5</td>
<td>3</td>
<td>2</td>
<td>10</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>10</td>
</tr>
<tr>
<td>Professional publications</td>
<td>10</td>
<td>19</td>
<td>60</td>
<td>89</td>
<td>-</td>
<td>-</td>
<td>14</td>
<td>14</td>
</tr>
<tr>
<td>PhD theses</td>
<td>21</td>
<td>6</td>
<td>18</td>
<td>45</td>
<td>4</td>
<td>8</td>
<td>25</td>
<td>37</td>
</tr>
</tbody>
</table>

Note: It is possible that output belongs to both AMC and VUmc. In that case, it is double counted since we are working with 2 separate systems.
Appendix Annual Report CCA 2017

1. Organization 4
2. Media attention 9
3. Awards 12
4. Patents / licenses 13
5. Funding of projects started in 2017 14

1. Organization CCA

Board AMC Oncological Center
- C.J.A. Punt, MD, PhD, Professor of Medical Oncology (chair)
- O. Busch, MD, PhD, Professor of Surgery
- J.E. van Hooft, MD, PhD, Gastroenterology and Hepatology
- C. Rasch, MD, PhD, Professor of Radiation Oncology
- G. Fons, MD, PhD, Gynecology
- J. Stoker, MD, PhD, Professor of Radiology
- M.J. Kersten, MD, PhD, Professor of Hematology
- J.P. Medema, PhD, Professor of Experimental Oncology and Radiobiology
- S.A. Heijmenberg, Internal Medicine

Board VUmc Cancer Center Amsterdam
- H.M.W. Verheul, MD, PhD, Professor of Medical Oncology (chair)
- G. Kazemier, MD, PhD, Professor of Surgical Oncology
- E. van Kessel, MBA, Program Manager Oncology
- Y. van Kooyk, PhD, Professor of Molecular Cell Biology and Immunology
- C.R. Leemans, MD PhD, Professor of Otolaryngology / Head & Neck Surgery
- B.J. Slotman, MD, PhD, Professor of Radiation Oncology
- P.J.F. Snijders, PhD, Professor of Pathology
- M.J. van de Vijver, MD, PhD, Professor of Pathology

Directors CCA

Prof. dr. J. P. Medema       Prof. dr. H.M.W. Verheul
Research programs

In order to align our research efforts and to foster collaboration between basic and clinical researchers in similar areas in the Cancer Center we envision the following specific research programs and themes as our main areas of cancer research:

1. Cancer biology and immunology
   In this program, basic cancer research on cancer biology and immunology is aimed at developing novel insight into the (patho)physiology of cancer and the immune system. Identification of novel targets for therapy and subgroup analysis will be a major goal and used to develop biomarkers and novel therapeutic modalities. The acquired biological and immunological insight will drive pre-clinical therapy development.
   For this program the following themes are identified:

   - Tumor biology
     Program leaders:

   ![Prof. dr. E. Eldering](image1)
   ![Dr. R.D.M. Steenbergen](image2)
   ![Prof. dr. L. Vermeulen](image3)
   ![Dr. R. Wolthuis](image4)
- **Tumor immunology**  
  Program leaders:

  ![Prof.dr. M. van Egmond](image1.png)  
  ![Prof.dr. T.D. de Gruijl](image2.png)  
  ![Prof.dr. A.P. Kater](image3.png)  
  ![Prof.dr. R.M. Luiten](image4.png)

- **Target discovery & Pre-clinical therapy development**  
  Program leaders:

  ![Prof.dr. V.W. van Beusechem](image5.png)  
  ![Prof.dr. R.H. Brakenhoff](image6.png)  
  ![Prof.dr. K.K. Krishnadath](image7.png)  
  ![Dr. M. Spaargaren](image8.png)

2. **Imaging & biomarkers**  
In this program, the focus of research is on translation of potential diagnostic and predictive biomarkers and imaging techniques that serve our mission to detect cancer early and to personalize cancer medicine. For this program the following themes are identified:

- **Imaging**  
  Program leaders:

  ![Prof.dr. G.A.M.S. van Dongen](image9.png)  
  ![Prof.dr. H.W.M. van Laarhoven](image10.png)  
  ![Prof.dr. A.G.J.M. van Leeuwen](image11.png)  
  ![Dr. J.M. Zijlstra](image12.png)
3. Treatment and Quality of Life
In this program, the research is focused on clinical implementation and evaluation of new leads for treatment strategies, in part based on discoveries from both program 1 and 2, and on improving quality of life. Therapy development also includes technology-driven research in Radiology and Radiotherapy and is supported by a phase I-II clinical trial unit. In addition, this program features our continued efforts to improve therapy as an (initiating) partner in large multi-center clinical trials. For this program the following themes are identified:

- **Clinical therapy development**
  Program leaders:
  - Prof.dr. M.I. van Berge-Henegouwen
  - Prof.dr. A.A. van de Loosdrecht
  - Prof. dr. S. Senan
  - Prof. dr. L.J.A. Stalpers

- **Evaluation of cancer care**
  Program leaders:
  - Dr. L.M. Buffart
  - Dr. H. Klümpen
  - Dr. M.G.H. van Oijen
  - To be determined
Education and training

The Cancer Center Amsterdam will provide education and training for new generations of students, physicians and scientists with focus on the latest developments in oncology and aiming to prepare the new generation for becoming internationally recognized researchers and clinicians. The already established Oncology Graduate School Amsterdam (Onderzoekschool Oncologie Amsterdam – OOA) plays an important role in this educational program for young career scientists. The Cancer Center will host about 500 PhD students, which will be member of the OOA. The OOA is a joint graduate school run by VUmc ('penvoerder'), AMC and NKI. The OOA, which has already been accredited by the KNAW since 1993, has a longstanding tradition of providing an education program made up of high quality courses on a wide range of topics in oncology. A highlight of the educational program is the three-day annual PhD student retreat, which focuses entirely on the research conducted by the students themselves, contributing significantly to active networking between groups. The oncology-specific courses will be supplemented with courses organized by amongst others, VUmc Centre for Training and Education and the AMC graduate school.

Next to providing a training and education program to PhD students, the Cancer Center Amsterdam will continue to organize the already established courses on oncology for (bio)medical and health sciences bachelor’s and master’s curricula of both universities. Currently, VUmc offers a Master’s program in Oncology, which is research-oriented and has a multidisciplinary character. Students are trained in state-of-the-art techniques in cancer research and therapy. At the UvA, the Master’s program in Biomedical Sciences offers an Oncology track, covering topics such as basic cell and molecular biology, genetics, development of novel strategies for cancer diagnosis and treatment. These tracks will be incorporated in our research institute and provide an influx of young talent.

In VUmc a committee for education and training is installed to initiate and supervise all training and educational activities within CCA at VUmc.

Furthermore, the interest of PhD students and Postdoctoral fellows are represented by a PhD/postdoc council.
2. **Media attention** (since there is no specific information about media attention of CCA available of AMC, this is not mentioned in this report)

<table>
<thead>
<tr>
<th>Topic</th>
<th>Medium</th>
<th>Name source</th>
<th>Date</th>
<th>URL</th>
<th>Researcher</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kanker de baas, maar je baan kwijt</td>
<td>Newspaper</td>
<td>Algemeen Dagblad and several regional newspapers</td>
<td>8-2-2017</td>
<td>website</td>
<td>Anema JR</td>
</tr>
<tr>
<td>Het vakgebied life sciences vraagt specifieke ICT-expertise: Samen bouwen aan een nieuwe onderzoekswelrd</td>
<td>internet</td>
<td></td>
<td>1-12-2017</td>
<td>website</td>
<td>Belien J</td>
</tr>
<tr>
<td>Gold medal life time achievement</td>
<td>Newspaper</td>
<td>Eindhovens dagblad</td>
<td>27-9-2017</td>
<td>website</td>
<td>Castelijns JA</td>
</tr>
<tr>
<td>Gold medal life time achievement</td>
<td>Magazine</td>
<td>Weekblad voor Ouder Amstel</td>
<td>27-9-2017</td>
<td>website</td>
<td>Castelijns JA</td>
</tr>
<tr>
<td>Gold medal life time achievement</td>
<td>Magazine</td>
<td>Spui Magazine</td>
<td>19-12-2017</td>
<td>website</td>
<td>Castelijns JA</td>
</tr>
<tr>
<td>Gold medal life time achievement</td>
<td>Magazine</td>
<td>Memorad</td>
<td>27-9-2017</td>
<td>website</td>
<td>Castelijns JA</td>
</tr>
<tr>
<td>local CpG in early-stage melanoma</td>
<td>newspaper and lots of news sites</td>
<td>Algemeen Dagblad-nu.nl and Interview for Dutch public radio NPO1 &quot;Radio 1 journaal&quot;</td>
<td>2-10-2017</td>
<td>website</td>
<td>de Grujl T</td>
</tr>
<tr>
<td>De anatomische les voor middelbare scholieren</td>
<td>college</td>
<td></td>
<td>2-11-2017</td>
<td></td>
<td>de Vries HE</td>
</tr>
<tr>
<td>Leven met een hersentumor</td>
<td>live television</td>
<td>Tijd voor Max (vanaf 7-44)</td>
<td>5-10-2017</td>
<td>website</td>
<td>de Witt Hamer P</td>
</tr>
<tr>
<td>Knowledge-based treatment planning for proton therapy</td>
<td>internet</td>
<td>Medical Physics</td>
<td>28-6-2017</td>
<td>website</td>
<td>Delaney A</td>
</tr>
<tr>
<td>Bezoek van KWF en donateurs</td>
<td></td>
<td></td>
<td>22-12-2017</td>
<td></td>
<td>den Haan JMM</td>
</tr>
<tr>
<td>Brain networks in neuro-oncology</td>
<td>Magazine</td>
<td>HersenMagazine</td>
<td>2-6-2017</td>
<td>website</td>
<td>Douw L</td>
</tr>
<tr>
<td>Predicting cognitive decline in surgical candidates</td>
<td>Online</td>
<td>nu.nl</td>
<td>31-01-2017</td>
<td>website</td>
<td>Douw L</td>
</tr>
<tr>
<td>Brain networks in neuro-oncology</td>
<td>Online</td>
<td>Vumc De Specialist</td>
<td>4-1-2017</td>
<td>website</td>
<td>Douw L</td>
</tr>
<tr>
<td>NWO Visitor grant is awarded to Dr. Omidreza Firuzi</td>
<td>Web</td>
<td>Amsterdaresearch.org website</td>
<td>9-11-2017</td>
<td>website</td>
<td>Giovannetti E</td>
</tr>
<tr>
<td>3D-Printed ‘Eyes’ Could Help Blind Children’s Faces Grow Naturally</td>
<td>internet</td>
<td>health articles</td>
<td>12-5-2017</td>
<td>website</td>
<td>Hartong D</td>
</tr>
<tr>
<td>3D Printed Eye Prostheses Can Help Children with Missing or Underdeveloped Eyes to Grow Normally</td>
<td>internet</td>
<td>3dprint.com</td>
<td>19-5-2017</td>
<td>website</td>
<td>Hartong D</td>
</tr>
<tr>
<td>Augenprothesen aus dem 3D-Drucker helfen Kindern mit Mikrophthalmie oder Anophthalmie</td>
<td>internet</td>
<td>3dgrenzenlos</td>
<td>22-5-2017</td>
<td>website</td>
<td>Hartong D</td>
</tr>
<tr>
<td>3D-printed ‘eye’ may help blind children’s faces to grow normally</td>
<td>internet</td>
<td>hoholok</td>
<td>17-5-2017</td>
<td>website</td>
<td>Hartong D</td>
</tr>
<tr>
<td>3D-printed ‘eye’ may help blind children’s faces to grow normally</td>
<td>internet</td>
<td>exos</td>
<td>31-5-2017</td>
<td>website</td>
<td>Hartong D</td>
</tr>
<tr>
<td>Bijdragen aan de natuurlijke groei van het gezicht van blinde kinderen met het 3D-afdrukkoog</td>
<td>internet</td>
<td>worldpronews</td>
<td>7-5-2017</td>
<td>website</td>
<td>Hartong D</td>
</tr>
<tr>
<td>Essential-Oils-Contact-allergy-and-Chemical-Composition</td>
<td>internet</td>
<td>NVDV</td>
<td>1-8-2017</td>
<td>website</td>
<td>Hartong D</td>
</tr>
<tr>
<td>Combinatie van vier eiwitten verbetert screening darmkanker</td>
<td>tijdschrift</td>
<td>Medisch Contact (door Henk Maassen)</td>
<td>21-11-2017</td>
<td></td>
<td>Jimenez C</td>
</tr>
<tr>
<td>Hot Paper from B/D-HPP Cancer Initiative: Stool proteomics study to improve colorectal cancer screening</td>
<td>on-line internationale nieuwsbrief</td>
<td>HUPOPOST</td>
<td>30-11-2017</td>
<td></td>
<td>Jimenez C</td>
</tr>
<tr>
<td>Con el proteoma cada paciente tendrá un tratamiento personalizado</td>
<td>spaanse krant</td>
<td>La Voz de Galicia</td>
<td>29-10-2017</td>
<td></td>
<td>Jimenez C</td>
</tr>
<tr>
<td>Lopen tegen Kanker</td>
<td>krant</td>
<td>Telegraaf</td>
<td>30-3-2017</td>
<td></td>
<td>Jimenez C</td>
</tr>
<tr>
<td>Topprestatie voor volgende stap in kankeronderzoek</td>
<td>krant</td>
<td>VUMC donateurskrant Eigenwijs</td>
<td>1-3-2017</td>
<td></td>
<td>Jimenez C</td>
</tr>
<tr>
<td>Adjuvant tamoxifen resistance</td>
<td>OncoTV</td>
<td></td>
<td>9-12-2017</td>
<td>website</td>
<td>Kruger D</td>
</tr>
<tr>
<td>Head and Neck Cancer: Make Sense Awareness Campaign (steering committee chair)</td>
<td>Multiple, i.e. Internet</td>
<td></td>
<td>18-09-2017</td>
<td>website</td>
<td>Leemans CR</td>
</tr>
<tr>
<td>De ins en outs van colitis na immununchekpointblokkade</td>
<td>internet</td>
<td>Immunoncologie.nl</td>
<td>1-2-2017</td>
<td>website</td>
<td>Neefjes-Borst A</td>
</tr>
<tr>
<td>Research into scientific misconduct</td>
<td>Internet</td>
<td>Retraction Watch</td>
<td>29-9-2017</td>
<td>website</td>
<td>Peeters CFW</td>
</tr>
</tbody>
</table>
Werken na kanker heilzaam en


Handezeeuw Bijblijven Springer Verlag 1-9-2017 website Rustomeyer T
Allergisch voor shampoo Television AvroTros 21-3-2017 website Rustomeyer T
Alpe d’Huzes grant Live & internet KWF 29-5-2017 website Steenbergen R
Alpe d’Huzes grant Radio KWF 2-6-2017 website Steenbergen R
Alpe d’Huzes grant Facebook KWF 29-5-2017 website Steenbergen R
VIVA 400 VIVA magazine ellines.com 23-11-2017 website Themeli M
KWF Ride for the Roses 2017 - gericht geven internet Ride for the Roses 20-6-2017 website van de Ven R
KWF Ride for the Roses Lansingerland facebook KWF Kankerbestrijding 3-9-2017 website van de Ven R
Genetic basis for alloimmunisation in SCD Blood Editorial (Blood Inside)https://ce0ozx88geoarkpajbbpj.sec.amc.nl/content/130/19/2051 1-11-2017 . van den Berg TK
Interview, immuuntherapie extra middel in de strijd tegen kanker magazine Instantmagazine 08-06-2017 Y. van Kooyk
Het belang van bewegen is allang bewezen Website UMCG 19-4-2017 website van Mechelen W
Rokers moeten zich voorbereiden op nog meer verboden Het Parool 29-7-2017 van Mechelen W
Bewegen en gezondheid Nieuwsshow (radio 1) 9-9-2017 van Mechelen W
Uit de bureaustoel Architectenweb p.64-67 1-3-2017 website van Mechelen W
Rookvrij Groningen vergt aanscherping landelijk rookverbod Stadzaken. Dagelijks online nieuws 25-7-2017 website van Mechelen W
Bewegen is een luxegoed geworden Trouw 8-9-2017 van Mechelen W
Wetenschappers realiseren zich meer dat hun inspanningen ook maatschappelijk toepasbaar moeten zijn. Online magazine VU Brussel 27-6-2017 website van Mechelen W
Cancer Immunotherapy (by Lenneke Cornelissen) popular scientific magazine Science Vie 1-6-2017 van Vliets S
Thesis defense Internet 28-11-2017 Promotie VUmc Veldhuijzen van Zanten SEM
Thesis defense Internet 28-11-2017 Promotie Lot & Sophie Veldhuijzen van Zanten SEM
Thesis defense Internet 28-11-2017 Flipbook VUmc Veldhuijzen van Zanten SEM
Thesis defense Internet 28-11-2017 Twitter VUmc Veldhuijzen van Zanten SEM
Thesis defense Internet 28-11-2017 Twitter Dr. D. van Vuurden Veldhuijzen van Zanten SEM
Nazorg per computer Krant Telegraaf 6-1-2017 website Verdonck-de Leeuw IM
Het Oncokompas: nazorg met en na kanker. Television Omroep Max,Hallo Nederland 10-1-2017 website Verdonck-de Leeuw IM
App die kankerpatiënt ondersteunt in basiszorg. Internet SKIPR 11-1-2017 website Verdonck-de Leeuw IM
De kanker van je afschrijven. Krant Dagbladen van de Holland Media Combinatie 4-2-2017 . Verdonck-de Leeuw IM
Nieuwe vorm van nazorg: stepped care na kanker werkt goed. Tijdschrift Mediator 22-3-2017 website Verdonck-de Leeuw IM
Psychosociale gevolgen van kanker. Internet Medtalks 6-4-2017 website Verdonck-de Leeuw IM
Werken na kanker heilzaam en Sociaal Bestek 2017-nr 3. website Verdonck-de Leeuw IM
<table>
<thead>
<tr>
<th>Topic</th>
<th>Medium</th>
<th>Name source</th>
<th>Date</th>
<th>URL</th>
<th>Researcher</th>
</tr>
</thead>
<tbody>
<tr>
<td>mogelijk.</td>
<td>Persbericht</td>
<td>ANP pers</td>
<td>5-7-2017</td>
<td>website</td>
<td>Leeuw IM</td>
</tr>
<tr>
<td>Uiterlijk belemmert vrouwen met kanker</td>
<td>Tijdschrift</td>
<td>Medische Oncologie</td>
<td>1-7-2017</td>
<td>website</td>
<td>Verdonck-de Leeuw IM</td>
</tr>
<tr>
<td>Oncokompas virtuele coach voor kankeroverlevers.</td>
<td>Internet</td>
<td>Genetic Engineering &amp; Biotechnology News</td>
<td>15-08-2017</td>
<td>website</td>
<td>Verdonck-de Leeuw IM</td>
</tr>
<tr>
<td>Liquid Biopsies mbt tumor edicated platelets en swarm intelligence</td>
<td>Internet</td>
<td>EurekAlert</td>
<td>14-08-2017</td>
<td>website</td>
<td>Würdinger T</td>
</tr>
<tr>
<td>Liquid Biopsies mbt tumor edicated platelets en swarm intelligence</td>
<td>Internet</td>
<td>Cancer Therapy Advisor</td>
<td>14-09-2017</td>
<td>website</td>
<td>Würdinger T</td>
</tr>
<tr>
<td>Liquid Biopsies mbt tumor edicated platelets en swarm intelligence</td>
<td>Internet</td>
<td>American Council on Science and Health</td>
<td>23-08-2017</td>
<td>website</td>
<td>Würdinger T</td>
</tr>
<tr>
<td>Liquid Biopsies mbt tumor edicated platelets en swarm intelligence</td>
<td>Internet</td>
<td>Genome Web</td>
<td>10-03-2017</td>
<td>website</td>
<td>Würdinger T</td>
</tr>
<tr>
<td>Liquid Biopsies mbt tumor edicated platelets en swarm intelligence</td>
<td>Internet</td>
<td>Tiscali News</td>
<td>16-08-2017</td>
<td>website</td>
<td>Würdinger T</td>
</tr>
<tr>
<td>Liquid Biopsies mbt tumor edicated platelets en swarm intelligence</td>
<td>Internet</td>
<td>Blik op Nieuws</td>
<td>15-08-2017</td>
<td>website</td>
<td>Würdinger T</td>
</tr>
<tr>
<td>Liquid Biopsies mbt tumor edicated platelets en swarm intelligence</td>
<td>Internet</td>
<td>VUmc</td>
<td>14-08-2017</td>
<td>website</td>
<td>Würdinger T</td>
</tr>
<tr>
<td>Liquid Biopsies mbt tumor edicated platelets en swarm intelligence</td>
<td>Internet</td>
<td>Medicalfacts</td>
<td>29-09-2017</td>
<td>website</td>
<td>Würdinger T</td>
</tr>
<tr>
<td>Liquid Biopsies mbt tumor edicated platelets en swarm intelligence</td>
<td>Internet</td>
<td>De kennis van nu</td>
<td>28-09-2017</td>
<td>website</td>
<td>Würdinger T</td>
</tr>
</tbody>
</table>
### Awards

(since there is no specific information about awards of CCA available of AMC, this is not mentioned in this report)

<table>
<thead>
<tr>
<th>Name award/honor</th>
<th>Awarded by</th>
<th>Date</th>
<th>Place Ceremony</th>
<th>Researcher</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chulabhorn Award</td>
<td>Chulabhorn Institute</td>
<td>18-12-2017</td>
<td>Bangkok</td>
<td>Brakenhoff R</td>
</tr>
<tr>
<td>Poster prize</td>
<td>Gordon Research Seminar - Microbial Adhesion and Signal Transduction</td>
<td>23-7-2017</td>
<td>Salve Regina University in Newport RI United States</td>
<td>Burggraaf MJ</td>
</tr>
<tr>
<td>Gold medal Life time achievement</td>
<td>European Society of head and neck radiology</td>
<td>29-9-2017</td>
<td>Lisbon</td>
<td>Castellijns JA</td>
</tr>
<tr>
<td>Awarded talk</td>
<td>International Magnetic Resonance in Medicine (ISMRM) - the world's largest MRI meeting - on color intensity projections (CIP) applied to breast cancer</td>
<td>22-4-2017</td>
<td></td>
<td>Cover K</td>
</tr>
<tr>
<td>PhD award for D. van Dinther</td>
<td>Dutch Tumor Immunology meeting</td>
<td>1-6-2017</td>
<td>Breukelen</td>
<td>de Haan JMM</td>
</tr>
<tr>
<td>KWF/Alpe Young Investigator Award</td>
<td>KWF</td>
<td>1-5-2017</td>
<td></td>
<td>de Lange J</td>
</tr>
<tr>
<td>Guest Professor, Hebei General Hospital, Shijiazhuang, China</td>
<td>Hebei General Hospital, Shijiazhuang, China</td>
<td>1-4-2017</td>
<td>Hebei General Hospital, Shijiazhuang, China</td>
<td>Dekker J</td>
</tr>
<tr>
<td>Award for Excellence of Applied Neuro-Oncology</td>
<td>22nd Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology</td>
<td>1-12-2017</td>
<td>San Fransisco</td>
<td>Klein M</td>
</tr>
<tr>
<td>Best Presentation Award</td>
<td>KWF Cancer Biology meeting</td>
<td>2017</td>
<td>Lunteren</td>
<td>Meel, H</td>
</tr>
<tr>
<td>Ellsworth Lecture in retinoblastoma</td>
<td>international society for genetic eye diseases and retinoblastoma</td>
<td>16-00-2017</td>
<td>Leeds, UK</td>
<td>Moll A</td>
</tr>
<tr>
<td>EHA CRTH winner and participant</td>
<td>EHA</td>
<td>1-11-2017</td>
<td>via EHA - brussel, Rome and EHA congress in Sweden</td>
<td>Nijhof I</td>
</tr>
<tr>
<td>1st Poster Prize VUmc Science Exchange Day 2017</td>
<td>Vaste Commissie Wetenschap Vumc</td>
<td>29-9-2017</td>
<td>Vumc, Amsterdam</td>
<td>Peeters CFW</td>
</tr>
<tr>
<td>Scientific Director for Advanced Studies in Lung Cancer</td>
<td>University of Zurich and the European School of Oncology</td>
<td>1-12-2017</td>
<td></td>
<td>Senan S</td>
</tr>
<tr>
<td>Chair, Advanced Radiation Therapy Committee</td>
<td>International Association for the Study of Lung Cancer</td>
<td>1-12-2017</td>
<td></td>
<td>Senan S</td>
</tr>
<tr>
<td>Honorary fellow American College of Radiology</td>
<td>American College of Radiology</td>
<td>21-5-2017</td>
<td>Washington DC</td>
<td>Slotman B</td>
</tr>
<tr>
<td>Jacob I Fabrikant award</td>
<td>International Stereotactic Radiosurgery Society</td>
<td>1-6-2017</td>
<td>Montreux, Switzerland</td>
<td>Slotman B</td>
</tr>
<tr>
<td>Selected co-president EUROGIN. This is a honorary position, which rewards persons who have made important contributions to the advance of research and clinical practice in the field of HPV associated diseases or other scientific activities of EUROGIN</td>
<td>EUROGIN</td>
<td>8-12-2017</td>
<td>Amsterdam</td>
<td>Snijders PJF</td>
</tr>
<tr>
<td>VIVA-400 knappe koppen</td>
<td>VIVA</td>
<td>23-11-2017</td>
<td>Undercurrent,Papaverweg 265</td>
<td>Themeli M</td>
</tr>
<tr>
<td>Professorship</td>
<td>VU/VUMC</td>
<td>1-9-2017</td>
<td>VU</td>
<td>van den Berg TK</td>
</tr>
<tr>
<td>Doctor honoris causa</td>
<td>Vrije Universiteit Brussel</td>
<td>23-5-2017</td>
<td>Aula Vrije universiteit Brussel</td>
<td>van Mechelen W</td>
</tr>
<tr>
<td>Eere-lidmaatschap Koninklijke Vereniging Leraren Lichamelijke Opvoeding</td>
<td>Koninklijke Vereniging Leraren Lichamelijke Opvoeding</td>
<td>8-9-2017</td>
<td>Aula Vrije universiteit Amsterdam</td>
<td>van Mechelen W</td>
</tr>
<tr>
<td>ASPASIA fellowship</td>
<td>NWO</td>
<td>9-7-2017</td>
<td></td>
<td>van Vliet SJ</td>
</tr>
</tbody>
</table>
## 4. Patents / licenses VUmc & AMC

<table>
<thead>
<tr>
<th>Name</th>
<th>Author(s)</th>
<th>Description</th>
<th>Number</th>
<th>Date assigned</th>
</tr>
</thead>
<tbody>
<tr>
<td>AMRIF B.V.</td>
<td>Brands, Seinen, Molthoff, Jansen, Oosting</td>
<td>Composition comprising alkaline phosphatase for use in the treatment of arthritides</td>
<td>17150448.4 - 1466</td>
<td>5-1-2018</td>
</tr>
<tr>
<td>Imaging apparatus and method of forming composite image from a plurality of source images</td>
<td>Cover KS, Lagerwaard FJ, Senan S</td>
<td>Color intensity project (CIP) technique for displaying time information in the hue applied to MRI of breast cancer</td>
<td>European application proceeding</td>
<td></td>
</tr>
<tr>
<td>Imaging apparatus and method of forming composite image from a plurality of source images</td>
<td>Cover KS, Lagerwaard FJ, Senan S</td>
<td>Color intensity project (CIP) technique for displaying time information in the hue applied to MRI of breast cancer</td>
<td>Licensed to BrainLab Germany for application in angiography</td>
<td></td>
</tr>
<tr>
<td>LAVA Therapeutics - VUmc License and Assignment Agreement</td>
<td>de Gruiti T, Verheul H, JJ van der Vliet</td>
<td>LAVA Therapeutics - VUmc License and Assignment Agreement</td>
<td>2016-0171</td>
<td>14-2-2017</td>
</tr>
<tr>
<td>BV CimCure - VUmc License agreement</td>
<td>Griffioen A, Huijbers E, Nowak-Sliwinska P</td>
<td>BV CimCure - VUmc License agreement</td>
<td>2017-0165</td>
<td>15-3-2017</td>
</tr>
<tr>
<td>Statines</td>
<td>Jansen G</td>
<td>CTI BioPharma - VUmc Option Agreement regarding the patents covering the synergistic therapeutic effect between Statins and Aminopeptidases (including Tosedostat)</td>
<td>EP17187127.0</td>
<td>21-8-2017</td>
</tr>
<tr>
<td>CTI BioPharma - VUmc Option Agreement regarding the patents covering the synergistic therapeutic effect between Statins and Aminopeptidases (including Tosedostat)</td>
<td>Jansen G</td>
<td>CTI BioPharma - VUmc Option Agreement regarding the patents covering the synergistic therapeutic effect between Statins and Aminopeptidases (including Tosedostat)</td>
<td>2017-0198</td>
<td>14-8-2017</td>
</tr>
<tr>
<td>Use of VHH antibodies against BMP4 for treatment of Barrett's esophagus (pre-cancer stage)</td>
<td>Krishnadath S</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HPV cervix cancer assay with normalized miRNA</td>
<td>Steenbergen R, Meijer C</td>
<td>EU17183100.1</td>
<td>still under examination</td>
<td></td>
</tr>
<tr>
<td>Swarm intelligence-enhanced diagnosis and therapy selection for cancer using tumor-educated platelets (Swarm)</td>
<td>Wurdinger T</td>
<td>NL2018391</td>
<td>17-2-2017</td>
<td></td>
</tr>
</tbody>
</table>
### 5. Funding of projects started in 2017

**Location VUMc**

<table>
<thead>
<tr>
<th>Project leader</th>
<th>Project title</th>
<th>Project type</th>
<th>Starting date</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bahce I</td>
<td>LBC - algemeen</td>
<td>CCA</td>
<td>01-07-2017</td>
<td>50,000,00</td>
</tr>
<tr>
<td>Bonjer H</td>
<td>Mesh Project</td>
<td>OVERIG 3e GS</td>
<td>21-03-2017</td>
<td>27,000,00</td>
</tr>
<tr>
<td>Bouma G</td>
<td>SERENITY studie</td>
<td>BeheerBV</td>
<td>01-10-2017</td>
<td>50,734,00</td>
</tr>
<tr>
<td>Cloos J</td>
<td>MRD detection in AML</td>
<td>BeheerBV</td>
<td>13-07-2017</td>
<td>568,348,00</td>
</tr>
<tr>
<td>Cover K</td>
<td>improved screening &amp; diagnosis</td>
<td>CCA</td>
<td>1-3-2017</td>
<td>94,679,00</td>
</tr>
<tr>
<td>de Lange J</td>
<td>Cohesion weakness: a unique cancer vulnerability of unknown origin</td>
<td>KWF YIG</td>
<td>2017</td>
<td>567,239,00</td>
</tr>
<tr>
<td>de Langen J</td>
<td>1LON18001 ZR Pembro Uiry stage</td>
<td>BeheerBV</td>
<td>01-06-2017</td>
<td>254,059,00</td>
</tr>
<tr>
<td>Dorsman J</td>
<td>Synthetic Lethal Interactions with Retinoblastoma Pathways</td>
<td>KWF</td>
<td>2017</td>
<td>190,810,00</td>
</tr>
<tr>
<td>Dorsman J</td>
<td>Implementation of novel CRISPR/Cas9 technologies</td>
<td>CCA Open Ronde</td>
<td>2017</td>
<td>210,358,00</td>
</tr>
<tr>
<td>Dorsman J</td>
<td>Functional Genomics of Fanconi Anemia Pathways using CRISPR-Cas9</td>
<td>FARF</td>
<td>2017</td>
<td>175,000,00</td>
</tr>
<tr>
<td>Giovannetti E</td>
<td>Microbiome pancreatic cancer</td>
<td>CCA</td>
<td>01-04-2017</td>
<td>75,000,00</td>
</tr>
<tr>
<td>Giovannetti E</td>
<td>Tumor-educated platelet profil</td>
<td>KWF 2016</td>
<td>01-04-2017</td>
<td>353,467,00</td>
</tr>
<tr>
<td>Hashemi S</td>
<td>1LON17009 - XALT3</td>
<td>BeheerBV</td>
<td>08-03-2017</td>
<td>33,942,00</td>
</tr>
<tr>
<td>Hashemi S</td>
<td>1LON17010 - BOOSTER</td>
<td>BeheerBV</td>
<td>01-05-2017</td>
<td>27,139,00</td>
</tr>
<tr>
<td>Iliaregui J</td>
<td>Biological control of T-all</td>
<td>CCA</td>
<td>01-03-2017</td>
<td>91,448,00</td>
</tr>
<tr>
<td>Hullemans E</td>
<td>Onstapingsmechanismen in de behandeling van hoog-gradiënte gliomen bij kinderen door middel van RNA sequencing.</td>
<td>Stichting Egbers</td>
<td>8-09-2017</td>
<td>47,180,00</td>
</tr>
<tr>
<td>Jimenez C</td>
<td>INTERROGATING PHOSPHOPROTEOME</td>
<td>KWF 2016</td>
<td>01-05-2017</td>
<td>835,908,75</td>
</tr>
<tr>
<td>Kaspers G</td>
<td>Splicing</td>
<td>VUmc fonds</td>
<td>01-06-2017</td>
<td>50,000,00</td>
</tr>
<tr>
<td>Kaspers G</td>
<td>Fertility add-on</td>
<td>Kika</td>
<td>10-01-2017</td>
<td>580,986,00</td>
</tr>
<tr>
<td>Kaspers G</td>
<td>KWF Insomnia</td>
<td>KWF 2016</td>
<td>01-11-2017</td>
<td>453,237,40</td>
</tr>
<tr>
<td>Kaspers G</td>
<td>Part 2 Later</td>
<td>OVERIG 3e GS</td>
<td>01-01-2017</td>
<td>144,532,00</td>
</tr>
<tr>
<td>Kazemier G</td>
<td>Microbiome 2017</td>
<td>CCA</td>
<td>01-07-2017</td>
<td>200,000,00</td>
</tr>
<tr>
<td>Kazemier G</td>
<td>Hypermethylated DNA</td>
<td>CCA</td>
<td>01-02-2017</td>
<td>100,000,00</td>
</tr>
<tr>
<td>Klein M</td>
<td>Brain Cognition</td>
<td>Bedrijf</td>
<td>1-10-2017</td>
<td>215,276,00</td>
</tr>
<tr>
<td>Koppers-Lalid D</td>
<td>Epitrans</td>
<td>KWF</td>
<td>01-03-2017</td>
<td>548,000,00</td>
</tr>
<tr>
<td>Melius R</td>
<td>lymph node stromal subsets</td>
<td>NWO</td>
<td>01-06-2017</td>
<td>262,117,00</td>
</tr>
<tr>
<td>Melius R</td>
<td>Non invasive biomarkers Crohn</td>
<td>MLD Stichting</td>
<td>01-12-2017</td>
<td>150,000,00</td>
</tr>
<tr>
<td>Morre S</td>
<td>Chlamydia trachomatis</td>
<td>RIVM</td>
<td>01-01-2017</td>
<td>68,595,00</td>
</tr>
<tr>
<td>Mutis T</td>
<td>Dual CAR T AML MM Kompass</td>
<td>OVERIG 3e GS</td>
<td>19-04-2017</td>
<td>675,152,00</td>
</tr>
<tr>
<td>Mutis T</td>
<td>5HEM17xxx CAR 3B CARNK HE0090</td>
<td>BeheerBV</td>
<td>01-06-2017</td>
<td>300,000,00</td>
</tr>
<tr>
<td>Mutis T</td>
<td>5HEM17027 Novartis CD32b</td>
<td>BeheerBV</td>
<td>14-07-2017</td>
<td>116,600,00</td>
</tr>
<tr>
<td>Noske D</td>
<td>A blood test for glioblastoma</td>
<td>OVERIG 3e GS</td>
<td>01-11-2017</td>
<td>60,000,00</td>
</tr>
<tr>
<td>Oprea-Lager D</td>
<td>Validation radiolabeled PSMA</td>
<td>CCA</td>
<td>08-05-2017</td>
<td>194,612,00</td>
</tr>
<tr>
<td>Oprea-Lager D</td>
<td>Sponsoring Astellas PSMA</td>
<td>OVERIG 3e GS</td>
<td>01-05-2017</td>
<td>60,000,00</td>
</tr>
<tr>
<td>Ossenkoppele G</td>
<td>HARMONY - IMI</td>
<td>EU-IMI</td>
<td>1-1-2017</td>
<td>150,000,00</td>
</tr>
<tr>
<td>Pegtel M</td>
<td>Exesosome-mediated delivery</td>
<td>CCA</td>
<td>01-01-2017</td>
<td>109,649,00</td>
</tr>
<tr>
<td>Pegtel M</td>
<td>LBC - algemeen</td>
<td>CCA</td>
<td>01-07-2017</td>
<td>1,340,000,00</td>
</tr>
<tr>
<td>Steenbergen R</td>
<td>KWF 10395</td>
<td>KWF 2016</td>
<td>1-9-2017</td>
<td>174,140,00</td>
</tr>
<tr>
<td>Steenbergen R</td>
<td>KWF 10781</td>
<td>KWF 2016</td>
<td>1-9-2017</td>
<td>546,269,20</td>
</tr>
<tr>
<td>Themelh M</td>
<td>CCA2014.1-17 Themel</td>
<td>CCA</td>
<td>24-04-2017</td>
<td>197,500,00</td>
</tr>
<tr>
<td>van de Donk N</td>
<td>5HEM17034 Nivo-Dara LAB-deel</td>
<td>BeheerBV</td>
<td>13-02-2017</td>
<td>917,796,00</td>
</tr>
<tr>
<td>van den Eertwegh A</td>
<td>10NC17015 CA209-511</td>
<td>BeheerBV</td>
<td>12-01-2017</td>
<td>90,971,00</td>
</tr>
<tr>
<td>van der Knaap M</td>
<td>VWM Trial</td>
<td>VUmc fonds</td>
<td>1-10-2017</td>
<td>100,000,00</td>
</tr>
<tr>
<td>van der Vliet J</td>
<td>1ONC17021 Res. overeenk. Lava</td>
<td>BeheerBV</td>
<td>1-5-2017</td>
<td>146,629,00</td>
</tr>
<tr>
<td>van Die I</td>
<td>RUBICON</td>
<td>NWO</td>
<td>01-11-2017</td>
<td>130,764,00</td>
</tr>
<tr>
<td>van Dongen G</td>
<td>5RING17xxx CRISTAL RNG0044</td>
<td>BeheerBV</td>
<td>12-04-2017</td>
<td>38,094,00</td>
</tr>
<tr>
<td>van Dongen G</td>
<td>5RING17006 CytomX RNG0046</td>
<td>BeheerBV</td>
<td>14-07-2017</td>
<td>122,859,00</td>
</tr>
<tr>
<td>van Grieken N</td>
<td>KWF 10613</td>
<td>KWF 2016</td>
<td>1-11-2017</td>
<td>678,480,50</td>
</tr>
<tr>
<td>van Vliet S. J.</td>
<td>Metabolism &amp; glycosylation patterns</td>
<td>CCA</td>
<td>01-06-2017</td>
<td>199,487,00</td>
</tr>
<tr>
<td>van Vliet S. J.</td>
<td>Aspasia</td>
<td>NWO - Aspasia</td>
<td>01-05-2017</td>
<td>200,000,00</td>
</tr>
<tr>
<td>Verbeke W</td>
<td>Varian Medical Systems, RapidPlanPT</td>
<td>OVERIG</td>
<td>01-07-2017</td>
<td>109,350,00</td>
</tr>
<tr>
<td>Verbeke W</td>
<td>Varian Medical Systems, Artificial Intelligence for radiotherapy</td>
<td>OVERIG</td>
<td>01-09-2017</td>
<td>250,000,00</td>
</tr>
<tr>
<td>Verhuer H</td>
<td>xxxxxx xxxx BAY 94-9343 / 18329</td>
<td>BeheerBV</td>
<td>27-09-2017</td>
<td>26,339,00</td>
</tr>
<tr>
<td>Verhuer H</td>
<td>Sunrise-2</td>
<td>CCA</td>
<td>01-01-2017</td>
<td>27,762,00</td>
</tr>
<tr>
<td>Verhuer H</td>
<td>1ONC17004 h Trunc-VEGF</td>
<td>BeheerBV</td>
<td>01-05-2017</td>
<td>272,500,00</td>
</tr>
<tr>
<td>Project leader</td>
<td>Project title</td>
<td>Project type</td>
<td>Starting date</td>
<td>Amount</td>
</tr>
<tr>
<td>----------------</td>
<td>---------------</td>
<td>--------------</td>
<td>---------------</td>
<td>--------</td>
</tr>
<tr>
<td>Westers T</td>
<td>HD Mass Cytometry CCA2016-5-28</td>
<td>CCA</td>
<td>01-09-2017</td>
<td>145,061,00</td>
</tr>
<tr>
<td>Wolf</td>
<td>4H syndroom en RNA polymerase</td>
<td>OVERIG 3e GS</td>
<td>15-2-2017</td>
<td>48,225,00</td>
</tr>
<tr>
<td>Würdinger T</td>
<td>CIRCA</td>
<td>STW/Hartstichting</td>
<td>1-12-2017</td>
<td>887,000,00</td>
</tr>
<tr>
<td>Würdinger T</td>
<td>WINDOW</td>
<td>Brain Tumour Charity</td>
<td>1-10-2017</td>
<td>1,750,000,00</td>
</tr>
<tr>
<td>Würdinger T</td>
<td>ELBA</td>
<td>ERC Marie Curie ITN</td>
<td>1-11-2017</td>
<td>3,400,000,00</td>
</tr>
<tr>
<td>Ylstra B</td>
<td>Chromorexis 10721</td>
<td>KWF 2016</td>
<td>01-11-2017</td>
<td>182,999,90</td>
</tr>
<tr>
<td>Zweegman S</td>
<td>HOVON 143</td>
<td>OVERIG 3e GS</td>
<td>01-03-2017</td>
<td>508,800,00</td>
</tr>
<tr>
<td>Zweegman S</td>
<td>HOVON 126</td>
<td>OVERIG 3e GS</td>
<td>11-07-2017</td>
<td>26,250,00</td>
</tr>
<tr>
<td>Zweegman S</td>
<td>KWF, Consortia,</td>
<td>KWF 2016</td>
<td>01-05-2017</td>
<td>627,649,00</td>
</tr>
<tr>
<td>Zweegman S</td>
<td>HOVON 143-b technician</td>
<td>OVERIG 3e GS</td>
<td>11-07-2017</td>
<td>67,297,20</td>
</tr>
</tbody>
</table>

*Note: only funding > €25k is presented*

### Location AMC*

<table>
<thead>
<tr>
<th>Project leader</th>
<th>Project title</th>
<th>Funding</th>
<th>Sponsor</th>
<th>Starting date</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bel A.</td>
<td>Child-tailored image guided adaptive radiotherapy: because children are not adults.</td>
<td>3</td>
<td>KWF Kankerbestrijding</td>
<td>01-01-2017</td>
<td>455,015,50</td>
</tr>
<tr>
<td>Bemelman W.A.</td>
<td>Transanal Minimally Invasive Surgery for alternative indications: Educational and Research program</td>
<td>4</td>
<td>Applied Medical</td>
<td>03-02-2017</td>
<td>50,000,00</td>
</tr>
<tr>
<td>Bemelman W.A.</td>
<td>FIT4Surgery Medtronic</td>
<td>4</td>
<td>Medtronic Trading NL B.V.</td>
<td>01-03-2017</td>
<td>20,000,00</td>
</tr>
<tr>
<td>Bemelman W.A.</td>
<td>A Pivotal, Prospective, Randomized, Controlled, Multicenter Superiority Clinical Study Comparing Standard Anastomosis Closure Technique to Standard Closure Technique Plus Sylys Surgical Sealant</td>
<td>4</td>
<td>Cohera Medical, Inc.</td>
<td>29-06-2017</td>
<td>113,758,00</td>
</tr>
<tr>
<td>Bergman J.J.G.H.M.</td>
<td>Slokdarmkanker en Barrett-slokdarm: vroeger vinden en genezen!</td>
<td>3</td>
<td>Stichting AMC Foundation (Vrijgesteld)</td>
<td>01-01-2017</td>
<td>37,500,00</td>
</tr>
<tr>
<td>Bergman J.J.G.H.M.</td>
<td>Clinical Trial to Evaluate Safety and Dose Response Using the C2 Cryoballoon Swipe Ablation System for the Treatment of Barrett's Esophagus.</td>
<td>4</td>
<td>C2 Therapeutics, Inc.</td>
<td>08-02-2017</td>
<td>56,710,00</td>
</tr>
<tr>
<td>Bergman J.J.G.H.M.</td>
<td>Next generation optical coherence tomography for improved detection of early Barrett's neoplasia.</td>
<td>3</td>
<td>Life Sciences Health TKI</td>
<td>31-03-2017</td>
<td>607,614,00</td>
</tr>
<tr>
<td>Bergman J.J.G.H.M.</td>
<td>Wide Area Transepithelial Sample Esophageal Biopsy combined with Computer Assisted 3-Dimensional Tissue Analysis For the Detection of High Grade Esophageal Dysplasia and Adenocarcinoma</td>
<td>4</td>
<td>CDx Diagnostics</td>
<td>25-11-2017</td>
<td>46,875,00</td>
</tr>
<tr>
<td>Besselink M.G.H.</td>
<td>Promzyme - Patient Reported Outcome Measures (PROMs) before and after pancreatic enZVME replacement therapy in pancreatic and periampullary cancer</td>
<td>4</td>
<td>Allergan Pharmaceuticals International Ltd</td>
<td>11-05-2017</td>
<td>60,000,00</td>
</tr>
<tr>
<td>Besselink M.G.H.</td>
<td>LEALIVE</td>
<td>4</td>
<td>Johnson &amp; Johnson Medical BV</td>
<td>01-07-2017</td>
<td>50,000,00</td>
</tr>
<tr>
<td>Besselink M.G.H.</td>
<td>MD-PhD Scholarship Maarten Korrel</td>
<td>1</td>
<td>AMC (Vrijgesteld)</td>
<td>01-12-2017</td>
<td>108,032,00</td>
</tr>
<tr>
<td>Besselink M.G.H.</td>
<td>Sponsorovereenkomst Promzyme - Nationaal Fonds tegen Kanker</td>
<td>3</td>
<td>Stichting Nationaal Fonds tegen kanker</td>
<td>01-12-2017</td>
<td>110,000,00</td>
</tr>
<tr>
<td>Bijlsma M.F.</td>
<td>MGH besmetting 2e ronde verlenging Veenstra</td>
<td>1</td>
<td>AMC</td>
<td>01-04-2017</td>
<td>35,000,00</td>
</tr>
<tr>
<td>Bijlsma M.F.</td>
<td>Interrogating the phosphoproteome for targets and markers in pancreatic cancer</td>
<td>3</td>
<td>KWF Kankerbestrijding</td>
<td>01-05-2017</td>
<td>176,321,00</td>
</tr>
<tr>
<td>Bijlsma M.F.</td>
<td>Liquid Biopsy platform vanuit alliantie instituut CCA - Advanced</td>
<td>1</td>
<td>AMC</td>
<td>01-12-2017</td>
<td>269,172,00</td>
</tr>
<tr>
<td>Project leader</td>
<td>Project title</td>
<td>Funding</td>
<td>Sponsor</td>
<td>Starting date</td>
<td>Amount</td>
</tr>
<tr>
<td>----------------</td>
<td>---------------</td>
<td>---------</td>
<td>---------</td>
<td>---------------</td>
<td>--------</td>
</tr>
<tr>
<td>Bins A.D.</td>
<td>A randomized, double blind, placebo controlled Phase III study of ODM 201 versus placebo in addition to standard androgen deprivation therapy and docetaxel in patients with metastatic hormone sensitive prostate cancer.</td>
<td>4</td>
<td>Covance Clinical and Periapproval Services SA</td>
<td>04-08-2017</td>
<td>81,496,00</td>
</tr>
<tr>
<td>Bins A.D.</td>
<td>Targeted immunotherapy directed against the dWR mutation signature: towards a prophylactic vaccine in patients with Lynch syndrome.</td>
<td>3</td>
<td>Stichting Sacha Swarttouw-Hijmans</td>
<td>07-12-2017</td>
<td>25,920,00</td>
</tr>
<tr>
<td>Buist M.R.</td>
<td>VilMP-project: Implementation of diagnostic laparoscopy in advanced stage ovarian cancer to guide initial treatment; either primary debulking surgery or neo-adjuvant chemotherapy</td>
<td>2</td>
<td>ZonMw</td>
<td>01-11-2017</td>
<td>46,902,00</td>
</tr>
<tr>
<td>Crezee J.</td>
<td>Development of patient specific treatment planning to enhance and optimize clinical effectiveness of hyperthermic intraperitoneal chemotherapy in colorectal cancer patients</td>
<td>3</td>
<td>KWF Kankerbestrijding</td>
<td>01-09-2017</td>
<td>563,765,00</td>
</tr>
<tr>
<td>Crezee J.</td>
<td>A dedicated high resolution small animal hyperthermia device to support translation of novel cancer therapies from lab to bedside</td>
<td>2</td>
<td>ZonMw</td>
<td>01-01-2017</td>
<td>411,852,00</td>
</tr>
<tr>
<td>Dekker E.</td>
<td>Evaluation of optimal intervals for colonoscopy surveillance: a randomized trial</td>
<td>3</td>
<td>KWF Kankerbestrijding</td>
<td>01-02-2017</td>
<td>1,142,391,50</td>
</tr>
<tr>
<td>Dekker E.</td>
<td>Evaluation of optimal intervals for colonoscopy surveillance: a randomized trial</td>
<td>3</td>
<td>KWF Kankerbestrijding</td>
<td>01-02-2017</td>
<td>525,275,00</td>
</tr>
<tr>
<td>Dekker E.</td>
<td>Fujfilm Linked Color Imaging versus high-definition white light endoscopy to increase the detection of polyps in patients with Lynch syndrome.</td>
<td>4</td>
<td>FUJIFILM Europe GmbH</td>
<td>26-01-2017</td>
<td>91,500,00</td>
</tr>
<tr>
<td>Dekker E.</td>
<td>Safety , feasibility and efficacy of the optical diagnosis strategy for diminutive polyps by trained and qualified endoscopists</td>
<td>3</td>
<td>Maag-Darm Stichting</td>
<td>01-10-2017</td>
<td>60,664,00</td>
</tr>
<tr>
<td>de Reijke T.M.</td>
<td>A Multinational, Phase 3, Randomized, Double blind, Placebo controlled efficacy and safety study of enzalutamide plus androgen deprivation therapy (9ADT) versus placebo plus ADT in patients with metastatic hormone sensitive prostate cancer (mHSPC).</td>
<td>4</td>
<td>INC Research UK Limited</td>
<td>16-01-2017</td>
<td>34,892,00</td>
</tr>
<tr>
<td>de Reijke T.M.</td>
<td>Cure for Cancer 2017-2021</td>
<td>3</td>
<td>Stichting Cure for Cancer</td>
<td>01-01-2017</td>
<td>915,345,00</td>
</tr>
<tr>
<td>Eldering E.F.</td>
<td>Understanding the active crosstalk between B cell lymphoproliferative malignancies and the immune system in order to improve anti-cancer immunotherapeutic approaches</td>
<td>3</td>
<td>Stichting AMC Foundation (Vrijgesteld)</td>
<td>01-01-2017</td>
<td>292,000,00</td>
</tr>
<tr>
<td>Eldering E.F.</td>
<td>Metacan</td>
<td>2</td>
<td>Europese Unie</td>
<td>01-09-2017</td>
<td>255,374,28</td>
</tr>
<tr>
<td>Eldering E.F.</td>
<td>CRISPR platform</td>
<td>1</td>
<td>AMC</td>
<td>01-12-2017</td>
<td>295,150,00</td>
</tr>
<tr>
<td>Fockens P.</td>
<td>Nieuwe Colon resectietechnieken</td>
<td>3</td>
<td>Stichting Europees Post Graduate GS School</td>
<td>01-09-2017</td>
<td>57,299,00</td>
</tr>
<tr>
<td>Grootenhuis M.A.</td>
<td>Improving Childhood Cancer Care when Parents Cannot be There - Reducing Medical Traumatic Stress in Childhood Cancer Patients by Bonding with a Robot Companion</td>
<td>2</td>
<td>Technologiestichting STW</td>
<td>01-10-2017</td>
<td>195,092,00</td>
</tr>
<tr>
<td>Guikema J.E.J.</td>
<td>De rol van de PI3-kinase/AKT/FOXO signaleringsroute in B cel maligniteiten</td>
<td>1</td>
<td>AMC</td>
<td>01-10-2017</td>
<td>75,300,00</td>
</tr>
<tr>
<td>Hazenberg M.D.</td>
<td>Antistoffen tegen AML , ontwikkeling van diagnostiek om</td>
<td>3</td>
<td>Stichting AMC Foundation</td>
<td>01-09-2017</td>
<td>50,000,00</td>
</tr>
<tr>
<td>Project leader</td>
<td>Project title</td>
<td>Funding</td>
<td>Sponsor</td>
<td>Starting date</td>
<td>Amount</td>
</tr>
<tr>
<td>----------------</td>
<td>------------------------------------------------------------------------------</td>
<td>---------</td>
<td>----------------------------------------------</td>
<td>---------------</td>
<td>-------------</td>
</tr>
<tr>
<td>Medema J.P.</td>
<td>recidief AML te voorkomen</td>
<td>2</td>
<td>(Vrijgesteld)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Koster J.J.B.</td>
<td>ITCC Pediatric Preclinical POC Platform</td>
<td>2</td>
<td>Europese Unie</td>
<td>01-01-2017</td>
<td>376.250,00</td>
</tr>
<tr>
<td>Krawczyk P.</td>
<td>DNA damage researchgroup Przemek</td>
<td>1</td>
<td>AMC</td>
<td>01-11-2017</td>
<td>96.500,00</td>
</tr>
<tr>
<td>Krawczyk P.</td>
<td>Boosting hyperthermia-based anticancer treatments by HSP90 inhibition</td>
<td>3</td>
<td>Erasmus MC</td>
<td>15-11-2017</td>
<td>338.192,00</td>
</tr>
<tr>
<td>Kremer L.C.M.</td>
<td>Health problems after 3D-planned pediatric radiotherapy: A nation-wide cohort study</td>
<td>3</td>
<td>KWF Kankerbestrijding</td>
<td>01-07-2017</td>
<td>543.100,00</td>
</tr>
<tr>
<td>Krishnadath K.K.</td>
<td>Circulating tumor cells for tailoring BMP targeted therapies CT34BMP</td>
<td>2</td>
<td>Europese Unie</td>
<td>01-07-2017</td>
<td>150.000,00</td>
</tr>
<tr>
<td>Medema J.P.</td>
<td>The Achilles Heel of mesenchymal colon cancers</td>
<td>3</td>
<td>KWF Kankerbestrijding</td>
<td>01-02-2017</td>
<td>1.169.422,00</td>
</tr>
<tr>
<td>Medema J.P.</td>
<td>MHV besmetting ronde 2 verlenging Bochve en Prasetyanti</td>
<td>1</td>
<td>AMC</td>
<td>01-04-2017</td>
<td>46.800,00</td>
</tr>
<tr>
<td>Medema J.P.</td>
<td>Oncode</td>
<td>3</td>
<td>Stichting Oncode Institute</td>
<td>01-09-2017</td>
<td>1.250.000,00</td>
</tr>
<tr>
<td>Naam</td>
<td>Thema</td>
<td>Groep</td>
<td>Datum</td>
<td>Bedrag</td>
<td></td>
</tr>
<tr>
<td>-----------------------------</td>
<td>------------------------------------------------------------------------</td>
<td>--------------------------------------------</td>
<td>--------------</td>
<td>---------------</td>
<td></td>
</tr>
<tr>
<td>Merks J.H.M.</td>
<td>Datamanagement SKION studies</td>
<td>AMC</td>
<td>01-09-2017</td>
<td>97.342,00</td>
<td></td>
</tr>
<tr>
<td>Pals S.T.</td>
<td>Agressieve lymfomen (matierele kosten project CG701002)</td>
<td>AMC</td>
<td>01-01-2017</td>
<td>60.000,00</td>
<td></td>
</tr>
<tr>
<td>Punt C.J.A.</td>
<td>A Multi-Centre Randomised Clinical Trial of biomarker-driven maintenance treatment for ir1-line metastatic colorectal cancer</td>
<td>Roche Nederland B.V.</td>
<td>01-11-2017</td>
<td>66.328,25</td>
<td></td>
</tr>
<tr>
<td>Saeed P.</td>
<td>Chirurgische anatomie orbitale apex</td>
<td>UitZicht</td>
<td>01-09-2017</td>
<td>25.000,00</td>
<td></td>
</tr>
<tr>
<td>Saeed P.</td>
<td>Orbita Tumoren</td>
<td>AMC</td>
<td>01-12-2017</td>
<td>16.477,00</td>
<td></td>
</tr>
<tr>
<td>Spaargaren M.</td>
<td>Towards targeted combination therapy to combat drug-resistance in mantle cell lymphoma and chronic lymphocytic leukemia</td>
<td>KWF Kankerbestrijding</td>
<td>01-02-2017</td>
<td>547.300,00</td>
<td></td>
</tr>
<tr>
<td>Stoker J.</td>
<td>CT/MRI beoordelingen</td>
<td>NIEUWE DEB IND</td>
<td>01-02-2017</td>
<td>44.880,62</td>
<td></td>
</tr>
<tr>
<td>Stoker J.</td>
<td>Project Advanced MRI of the bowel</td>
<td>AMC</td>
<td>01-06-2017</td>
<td>264.000,00</td>
<td></td>
</tr>
<tr>
<td>Stoker J.</td>
<td>Ultra-low-dose chesf CT as an alternative for chest X-ay in imaging patients suspected of non-traumatic pulmonary disease at the Emergency Department</td>
<td>ZonMw</td>
<td>01-12-2017</td>
<td>580.755,00</td>
<td></td>
</tr>
<tr>
<td>Tanis P.J.</td>
<td>LifeCell</td>
<td>AMC</td>
<td>01-05-2017</td>
<td>214.246,00</td>
<td></td>
</tr>
<tr>
<td>Tanis P.J.</td>
<td>BIOPLEX 2</td>
<td>LifeCell EMEA Ltd.</td>
<td>13-06-2017</td>
<td>62.558,00</td>
<td></td>
</tr>
<tr>
<td>van Berge Henegouwen M.L.</td>
<td>Distribution of lymph node metastases in esophagael carcinoma (TIGER).</td>
<td>Olympus Nederland B.V.</td>
<td>01-06-2017</td>
<td>40.000,00</td>
<td></td>
</tr>
<tr>
<td>van den Bos C.</td>
<td>Pediatric relapsed acute leukemia: Sleep, fatigue, additional costs to the family and their effect on quality of life</td>
<td>Crediteurenadmm. VUmc, p/a Proforce Service Center</td>
<td>01-01-2017</td>
<td>47.50</td>
<td></td>
</tr>
<tr>
<td>van der Molen H.F.</td>
<td>NCoB dienstverlening 2017</td>
<td>Ministerie van SZW</td>
<td>01-01-2017</td>
<td>625.718,00</td>
<td></td>
</tr>
<tr>
<td>Vantertop W.P.</td>
<td>Voorloper fellowship</td>
<td>AMC</td>
<td>01-01-2017</td>
<td>23.947,00</td>
<td></td>
</tr>
<tr>
<td>van de Vijver M.J.</td>
<td>Genetic properties of breast carcinomas associated with cancer-immune interactions</td>
<td>KWF Kankerbestrijding</td>
<td>01-11-2017</td>
<td>721.382,00</td>
<td></td>
</tr>
<tr>
<td>van Gulik T.M.</td>
<td>Mushroom-derived phytochemicals for treatment of perihilar cholangiocarcinoma</td>
<td>Stichting Surgical Research Foundation</td>
<td>15-02-2017</td>
<td>48.175,00</td>
<td></td>
</tr>
<tr>
<td>van Gulik T.M.</td>
<td>Aanstelling L. Franken</td>
<td>Stichting AMC Foundation (Vrijgesteld)</td>
<td>15-11-2017</td>
<td>51.755,00</td>
<td></td>
</tr>
<tr>
<td>van Kampen A.H.C.</td>
<td>Aanstelling Elena Merino</td>
<td>AMC</td>
<td>15-03-2017</td>
<td>253.395,00</td>
<td></td>
</tr>
<tr>
<td>van Kampen A.H.C.</td>
<td>Modelling immune processes AI/O</td>
<td>AMC</td>
<td>01-12-2017</td>
<td>230.471,00</td>
<td></td>
</tr>
<tr>
<td>van Laarhoven H.W.M.</td>
<td>PDL-1 targeting in resectable oesophageal cancer: a phase IB feasibility study of Atezolizumab and chemoradiation (PERFECT)</td>
<td>Roche Nederland B.V.</td>
<td>02-03-2017</td>
<td>887.360,00</td>
<td></td>
</tr>
<tr>
<td>van Laarhoven H.W.M.</td>
<td>Organoid and organotypic cultures to Personalize pancreatic cancer Treatment (OPT study)</td>
<td>Stichting voor Lever en Maag- Darmonderzoek</td>
<td>27-03-2017</td>
<td>130.000,00</td>
<td></td>
</tr>
<tr>
<td>van Laarhoven H.W.M.</td>
<td>Declaraties van kosten, ten behoeve van POCOP en PACAP</td>
<td>Integraal Kankercentrum Nederland</td>
<td>15-03-2017</td>
<td>101.830,00</td>
<td></td>
</tr>
<tr>
<td>van Laarhoven H.W.M.</td>
<td>A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-Oncology Study in Participants with Advanced Gastric Cancer (FRACTION-Gastric Cancer)</td>
<td>Bristol-Myers Squibb Int. Corp.</td>
<td>08-08-2017</td>
<td>563.147,25</td>
<td></td>
</tr>
<tr>
<td>van Laarhoven H.W.M.</td>
<td>Development of a platform for next-generation DNA sequencing based personalized treatment for cancer patients: protocol to obtain biopsies from patients with metastatic cancer (CPCT-02)</td>
<td>Stichting Hartwig Medical Foundation</td>
<td>30-10-2017</td>
<td>84.000,00</td>
<td></td>
</tr>
<tr>
<td>van Laarhoven H.W.M.</td>
<td>Critics2</td>
<td>Antonie van Leeuwenhoek Ziekenhuis</td>
<td>18-09-2017</td>
<td>29.069,80</td>
<td></td>
</tr>
<tr>
<td>Name</td>
<td>Title</td>
<td>Funding Body</td>
<td>Amount (€)</td>
<td>Start Date</td>
<td>End Date</td>
</tr>
<tr>
<td>-----------------------------</td>
<td>-----------------------------------------------------------------------</td>
<td>---------------------------</td>
<td>------------</td>
<td>----------------</td>
<td>--------------</td>
</tr>
<tr>
<td>Van Laarhoven H.W.M.</td>
<td>Determination of treatment toxicity and HER2 status in esophagogastric cancer patients in the Netherlands ML39597</td>
<td>Roche Nederland B.V.</td>
<td>282.000,00</td>
<td>28-09-2017</td>
<td></td>
</tr>
<tr>
<td>Van Leeuwen A.G.J.M.</td>
<td>Biomedical Research</td>
<td>AMC</td>
<td>40.000,00</td>
<td>01-01-2017</td>
<td></td>
</tr>
<tr>
<td>Van Leeuwen A.G.J.M.</td>
<td>FOIPO</td>
<td>Europese Unie</td>
<td>177.599,00</td>
<td>01-01-2017</td>
<td></td>
</tr>
<tr>
<td>Van Leeuwen A.G.J.M.</td>
<td>Emmet</td>
<td>AMC</td>
<td>26.916,00</td>
<td>01-10-2017</td>
<td></td>
</tr>
<tr>
<td>Van Leeuwen A.G.J.M.</td>
<td>OCTIC</td>
<td>Rijksdienst voor Ondernemend Nederland</td>
<td>397.200,00</td>
<td>01-09-2017</td>
<td></td>
</tr>
<tr>
<td>Van Leeuwen A.G.J.M.</td>
<td>Advanced optical imaging of the oesophagus during cancer therapy</td>
<td>AMC</td>
<td>60.000,00</td>
<td>15-03-2017</td>
<td></td>
</tr>
<tr>
<td>Van Leeuwen A.G.J.M.</td>
<td>EV Diagnostics for monitoring therapy by CARS (project 3.4)</td>
<td>Technologiestichting STW</td>
<td>84.628,00</td>
<td>01-01-2017</td>
<td></td>
</tr>
<tr>
<td>Van Noesel C.J.M.</td>
<td>Implementatie van BRCA diagnostiek bij patiënten met ovariumcarcinoom</td>
<td>AstraZeneca BV</td>
<td>73.330,00</td>
<td>10-10-2017</td>
<td></td>
</tr>
<tr>
<td>Van Oijen M.G.H.</td>
<td>Evidence-based care for colorectal cancer in The Netherlands during 2008-2015: a retrospective cohort study and provider survey of the Dutch Colorectal Cancer Group (DCCG)</td>
<td>Roche Nederland B.V.</td>
<td>100.150,00</td>
<td>13-03-2017</td>
<td></td>
</tr>
<tr>
<td>Vermeulen L.</td>
<td>MHV besmetting ronde 2 verlenging K. Lenos</td>
<td>AMC</td>
<td>37.200,00</td>
<td>01-04-2017</td>
<td></td>
</tr>
<tr>
<td>Vermeulen L.</td>
<td>Spatiotemporal Dynamics of therapy response and resistance in gastrointestinal malignancies</td>
<td>KWF Kankerbestrijding</td>
<td>578.196,00</td>
<td>01-08-2017</td>
<td></td>
</tr>
<tr>
<td>Vermeulen L.</td>
<td>Using Molecular Subtypes to predict anti-EGFR Responses in metastatic Colorectal Cancer</td>
<td>KWF Kankerbestrijding</td>
<td>557.347,00</td>
<td>01-10-2017</td>
<td></td>
</tr>
<tr>
<td>Vermeulen L.</td>
<td>Beursaanvraag Neutral competition in expanding malignancies of the GI tract</td>
<td>AMC</td>
<td>280.000,00</td>
<td>01-11-2017</td>
<td></td>
</tr>
<tr>
<td>Vermeulen L.</td>
<td>Tegengaan van overbehandeling van colorectale kanker door implementatie van nieuwe moleculaire diagnostiek</td>
<td>Innovatiefonds Zorgverzekeraars</td>
<td>383.030,00</td>
<td>01-09-2017</td>
<td></td>
</tr>
<tr>
<td>Versteeg R.</td>
<td>The R2 bioinformatics platform: consolidation and expansion for the next decennium</td>
<td>AMC</td>
<td>240.000,00</td>
<td>01-01-2017</td>
<td></td>
</tr>
<tr>
<td>Versteeg R.</td>
<td>Ellen Westerhout Oncogenomics 3,6 maand 26.659</td>
<td>AMC</td>
<td>26.659,00</td>
<td>01-04-2017</td>
<td></td>
</tr>
<tr>
<td>Wilmink J.W.</td>
<td>Something old, something new; repurposing already-approved metabolic drugs to target IDH1/2 mutations in cancer</td>
<td>KWF Kankerbestrijding</td>
<td>181.137,00</td>
<td>01-11-2017</td>
<td></td>
</tr>
<tr>
<td>Wilmink J.W.</td>
<td>A phase III study of BBI-608 plus nab-Paclitaxel with Gemcitabine in Adult Patients with Metastatic Pancreatic Adenocarcinoma as amended from time to time and incorporated herein by reference (hereinafter referred to as the protocol )</td>
<td>Chiltern International BV</td>
<td>29.305,00</td>
<td>03-02-2017</td>
<td></td>
</tr>
</tbody>
</table>

*Note: only funding > €25k is presented*